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Mechanisms underlying cognitive 
deficits in a mouse model for 
Costello Syndrome are distinct 
from other RASopathy mouse 
models
Jadwiga Schreiber1,2, Laura-Anne Grimbergen1,2, Iris Overwater1,2, Thijs van der Vaart1,2, 
Jeffrey Stedehouder3, Alberto J. Schuhmacher4, Carmen Guerra4, Steven A. Kushner  2,3, Dick 
Jaarsma1 & Ype Elgersma1,2
RASopathies, characterized by germline mutations in genes encoding proteins of the RAS-ERK 
signaling pathway, show overlapping phenotypes, which manifest themselves with a varying severity 
of intellectual disability. However, it is unclear to what extent they share the same downstream 
pathophysiology that underlies the cognitive deficits. Costello syndrome (CS) is a rare RASopathy 
caused by activating mutations in the HRAS gene. Here we investigated the mechanisms underlying 
the cognitive deficits of HRasG12V/G12V mice. HRasG12V/G12V mice showed robust upregulation of ERK 
signaling, neuronal hypertrophy, increased brain volume, spatial learning deficits, and impaired 
mGluR-dependent long-term depression (LTD). In contrast, long-term potentiation (LTP), which is 
affected in other RASopathy mouse models was unaffected. Treatment with lovastatin, a HMG-CoA-
Reductase inhibitor which has been shown to rescue the behavioral phenotypes of mouse models of 
NF1 and Noonan syndrome, was unable to restore ERK signaling and the cognitive deficits of HRasG12V/
G12V mice. Administration of a potent mitogen-activated protein kinase (MEK) inhibitor rescued the 
ERK upregulation and the mGluR-LTD deficit of HRasG12V/G12V mice, but failed to rescue the cognitive 
deficits. Taken together, this study indicates that the fundamental molecular and cellular mechanisms 
underlying the cognitive aspects of different RASopathies are remarkably distinct, and may require 
disease specific treatments.
In the last decade, several neurodevelopmental syndromes have been identified with germline mutations within 
key components of the highly conserved RAS (rat sarcoma viral oncogene homolog)-ERK (extracellular signal 
regulated kinase) signaling pathway1–3. These syndromes, including neurofibromatosis Type I (NF1), Noonan 
syndrome, LEOPARD syndrome, cardio-facio-cutaneous (CFC) syndrome, Costello syndrome, and Legius 
syndrome show significant phenotypic overlap and are referred to as RASopathies, the most common group of 
neurodevelopmental syndromes, affecting approximately 1 in 1,000 individuals4. RASopathies patients typically 
present a combination of facial and skin abnormalities, heart defects, a predisposition to specific cancers, and 
developmental delay including central nervous system (CNS) abnormalities, cognitive dysfunction, and behav-
ioral impairments.
The RAS-ERK pathway operates as a functional hub that integrates extracellular signals through cell sur-
face receptor activation (e.g., tyrosine kinases receptors (RTKs), and transmits these signals intracellularly5, 6. 
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Upon activation, RAS, a small guanosine nucleotide-bound GTPase, switches to an active guanosine triphosphate 
(GTP)-bound form and activates downstream targets of the pathway. RAS-GTP inactivates rapidly by conversion 
to RAS-guanosine diphosphate (RAS-GDP) through its intrinsic GTPase7. This process can be accelerated by 
GTPase activating proteins (GAPs) such as Neurofibromin 1 (NF1).
In mitotic cells, the RAS-ERK pathway regulates fundamental processes such as the cell cycle, cellular growth, 
differentiation, and senescence, all of which are critical to normal development. Not surprisingly, the RAS-ERK 
pathway has been studied extensively in the context of oncogenesis. However, involvement of the RAS-ERK 
pathway in a number of neurological syndromes has refocused attention to the function of these proteins in 
post-mitotic neuronal cell types3. Studies of several mouse models of RASophaties, including NF1, NS, and 
Legius syndrome, have demonstrated that dysregulation of the RAS-ERK pathway causes behavioral and learning 
deficits, altered synaptic plasticity, and structural brain abnormalities8–11. Moreover, these studies demonstrated 
the potential of inhibitors of the RAS-ERK pathway as a putative therapy for the cognitive deficits8–10.
Costello syndrome (CS) is a rare RASopathy, with a estimated prevalence of 1 in 1.25 million people12, 13. 
CS is caused by gain-of-function missense mutations in the HRAS gene, of which the substitution of Glycine to 
Serine (G12S) at codon 12 in exon 1 is the most prevalent, constituting 80% of CS cases7, 14, 15. The G12S mutation 
reduces the intrinsic GTPase activity of the HRAS protein, with a concomitant increase in binding affinity and 
activation of its downstream targets including ERK and PI-3 kinase6. An HRASG12V/G12V mouse model of CS has 
been generated which displays several of the phenotypic abnormalities observed in CS patients, including facial 
dysmorphia and cognitive impairment16, 17. However, the cellular mechanism underlying these deficits as well as 
the ability to reverse them has not yet been studied.
Here we show that HRASG12V/G12V mice, present with strong hyperactivation of the ERK signaling pathway, 
neuronal hypertrophy with concomitantly increased brain weight, and a spatial learning deficit in the Morris 
water maze test. At the physiological level we observed normal long-term potentiation (LTP) but impaired 
mGluR-mediated long-term depression (LTD). Treatment with lovastatin, a drug that rescues learning deficits 
in NF1 and Noonan syndrome mouse models, had no effect on pERK levels and did not rescue the learning 
deficits of HRasG12V/G12V mice. Notably however, administration of a mitogen-activated protein kinase kinase 
(MEK) inhibitor normalized the ERK upregulation and rescued the mGluR-LTD deficit of HRasG12V/G12V mice, 
but the cognitive deficits remained persistent. Our results indicate that although all RASopathies are charac-
terized by increased RAS-ERK signaling, their downstream effectors and therapeutic targets appear to be quite 
distinct.
Results
Increased RAS-ERK signaling in HRasG12V/G12V mice. To better understand the role of HRAS protein 
in neuronal functioning, we studied a mouse model for Costello syndrome (CS)16. This mouse carries a germline 
targeted point mutation introduced into the HRAS gene: glycine (G) to valine (V) at amino acid 12 (G12V), lead-
ing to expression of a constitutively active HRAS protein (from here referred to as HRASG12V protein or HRasG12V/
G12V mice). The G12V mutation has been found in a number of CS patients and is associated with very severe 
disease manifestations14, 18, 19. As described previously, mutant HRasG12V/G12V mice were born at the expected 
Mendelian ratio, were fertile, survived at rates comparable to those of their wild-type littermates, and displayed 
several of the phenotypic abnormalities observed in CS patients, including facial dysmorphia16, 17. In examining 
protein expression, we observed a 50% decrease in HRAS protein in hippocampal lysates of HRasG12V/G12V mice 
(t8 = 5.34, P < 0.01; Fig. 1A,B), which was confirmed by immunohistochemistry (Fig. 1C). Hence, the level of 
HRASG12V protein in homozygous HRasG12V/G12V mice might resemble the HRASG12V protein level of heterozygous 
patients.
To evaluate whether constitutively active HRAS leads to hyperactivation of the RAS-ERK pathway, we assessed 
the level of ERK phosphorylation (pERK) in hippocampal lysates of adult HRasG12V/G12V mice. Immunoblotting 
revealed a significant increase in phosphorylated ERK isoforms ERK1 (pERK 44) and ERK2 (pERK 42) 
(t8 = −5.92, P < 0.01, whereas total ERK was similar between the genotypes (Fig. 1A,B). In accordance with this 
result, immunohistochemistry revealed increased amounts of pERK throughout the HRasG12V/G12V brain, particu-
larly in the hippocampus and cortex (Fig. 1D,E).
Hypertrophy of brain and pyramidal neurons in HRasG12V/G12V mice. Similar to the previous descrip-
tions of the CS mouse model, we observed that most HRasG12V/G12V mice could be clearly distinguished from their 
wild-type (WT) littermates by their blunt nose and prominent forebrain16, 17. After careful dissection of the brain 
from the skull, we observed a difference in the overall shape of the brain of HRasG12V/G12V mice (Fig. 2A). Brain 
weight was increased by 22% in HRasG12V/G12V mice (F1,11 = 31.59, P < 0.01; Fig. 2B), while total body weight was 
unchanged (F1,11 = 0.15, P = 0.71). Measurement of the surface area of several brain regions on level-matched cor-
onal brain sections revealed that HRasG12V/G12V mice had a significantly larger surface area of cortex (t6 = −13,05, 
P < 0.01), striatum (t6 = −10.27, P < 0.01), and corpus callosum (t6 = −12.49, P < 0.01, Fig. 2D). Moreover, 
both the cortex (t6 = −4.05, P < 0.01) and corpus callosum (t6 = −2.56, P < 0.05) were significantly thicker in 
HRasG12V/G12V mice (Fig. 2C,E). In addition, analysis of neuronal cell size was performed in the deep lamina of 
the S1 somatosensory cortex in transverse sections stained for DAPI, NeuN and FOXP2, which is expressed by a 
subset of neurons in layer V and VI. The diameter of both NeuN+FOXP2 negative and NeuN+FOXP2 positive 
neurons was significantly larger in HRasG12V/G12V mice (upper-layer neurons: t6 = −3.58, P < 0.05; deep-layer neu-
rons t6 = −4.76, P < 0.01; Fig. 2F–H). These results are in agreement with previous observations from a transgenic 
HRasG12V mouse model, which showed increased brain volume and larger pyramidal cells in layers V-VI of the 
motor and somatosensory cortex in adult mice20, 21.
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Learning impairment in HRasG12V/G12V mice in the Morris water maze (MWM). Learning defi-
cits are among the most frequent cognitive limitations observed in CS patients22 as well as other RASopathies3, 
and are also observed in mouse models of CS, NF1, NS, and Legius syndrome. In particular, impairments of 
hippocampus-dependent spatial learning in the Morris water maze (MWM) have been reported in every 
RASopathy mouse model examined thus far (Table 1). During the MWM training, mice learn to use visual cues 
positioned outside a pool to find a hidden escape platform submerged beneath the surface of the opaque water. 
Previously, it has been shown that HRasG12V/G12V mice in the mixed 129-C57BL/6 background showed a learning 
deficit in the MWM test17. However, it has been frequently been observed that behavioral phenotypes are lost 
upon backcrossing. In fact expression of NF1, the most important regulator of RAS, is 30% lower in animals 
on the 129 strain compared to the animals on the C57BL/6 strain23, and the learning deficits in NF1 mice are 
exclusively observed in the mixed (F1) 129-C57BL/6 background8, 24, 25. Hence, to determine whether the MWM 
phenotype of HRasG12V/G12V mice is still present upon backcrossing the mutants for over 20 generations in the 
C57BL/6 background, we repeated the MWM experiment. We observed that both genotypes showed a reduc-
tion in their latency to find the hidden platform, but HRasG12V/G12V mice exhibited significantly longer latencies 
compared to wild-type mice (between subject comparison day 1–9: F1,30 = 12.78, P < 0.01; day 10–14: F1,15 = 6.53, 
P < 0.05; Fig. 3A). There were no significant differences in swimming speed (between subject comparison, effect 
of genotype: F1,30 = 0.28, P = 0.60) or thigmotaxis (F1,30 = 190, P = 0.18).
After 5 days of hidden platform training, the platform was removed and mice were subjected to a probe 
trial to test spatial memory. Wild-type mice demonstrated a focused search pattern with the majority of their 
time spent in close proximity to the trained position of the platform (target quadrant (TQ) versus other quad-
rants; t16 = −3.46, P < 0.01). In contrast, HRasG12V/G12V mice showed no significant preference for the target quad-
rant compared to the other three quadrants and were significantly different from wild-type mice (TQ vs. other 
Figure 1. Hyperactivity of RAS-ERK signaling in HRasG12V/G12V mice. (A) Western blots of hippocampal 
lysates taken from wild-type and HRasG12V/G12V mice using antibodies for HRAS, pERK 42/44 (pERK), ERK 
42/44 (ERK) and actin. (B) Quantification of Western blots showing a significant increase in pERK (t8 = −5.92, 
P < 0.01) and a significant decrease in expression of HRAS protein in HRasG12V/G12V mice compared to their 
wild-type littermates (t8 = 5.34, P < 0.01). Data are presented as mean ± SEM of percentage of WT level set 
as 100% from 5 mice per genotype (n = 5/genotype). Statistical test: unpaired two-tailed t-test, *P < 0.05, 
**P < 0.01. (C) Visualisation of β-galactosidase activity of the IRES–β-geo cassette integrated into the mutated 
HRAS gene (LacZ; blue) combined with an HRAS staining (DAB; brown) indicating successful recombination 
and expression of HRASG12V, however lower amounts of HRAS protein are seen in HRasG12V/G12V mice compared 
to WT littermates. Right panel: Zoomed-in image of hippocampus. (D,E) DAB staining using pERK 42/44 
and ERK 42/44 antibodies revealed increased levels of ERK phosphorylation in HRasG12V/G12V mouse brain 
slices compared to WT (D), but no difference in the level of expression and distribution of total ERK between 
genotypes (E).
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Figure 2. Hypertrophy of brain and pyramidal neurons in HRasG12V/G12V mice. (A) Overview images of brains 
dissected from HRasG12V/G12V mice and wild-type littermates, indicating the increased brain weight of HRasG12V/
G12V mice. (B) HRasG12V/G12V mice have significantly increased brain weight (effect of genotype: F1,11 = 31.59, 
P < 0.01) but show no difference in body weight (effect of genotype: F1,11 = 0.15, P = 0.71). Data are presented 
as individual values of brain vs. body weight from wild-type n = 7 mice, HRasG12V/G12V n = 6 mice. Statistical 
test: one-way MANOVA. (C) Coronal cross-section comparison between HRasG12V/G12V and wild-type mice. 
Upper panel: As an example, the measurements of surface area of corpus callosum (CC) are indicated by 
yellow lines; cortical thickness was measured as indicated by the black line in the left hemisphere. Lower panel: 
Zoomed-in images of CC in the midline of the section of WT and HRasG12V/G12V mice represent thicker CC in 
HRasG12V/G12V mice. (D,E) Quantification of the area measurements revealed significantly bigger surface areas 
of cortex (t6 = −13.05, P < 0.01), striatum (t6 = −10.27, P < 0.01) and corpus callosum (t6 = −12.49, P < 0.01) 
(D) as well as a thicker cortex (t6 = −4.05, P < 0.01) and CC (t6 = −2.56, P < 0.05) (E). (F) Quantification of 
cell size revealed a significantly bigger soma size of NeuN- and FoxP2-positive cells as well as in NeuN-positive 
pyramidal neurons in HRasG12V/G12V mice (for NeuN-positive cells t6 = −3.58, P < 0.05; for NeuN- and FoxP2-
positive cells t6 = −4.76, P < 0.01). (G,H) Images of coronal slices of the cortex stained for DAPI (blue) and 
NeuN (red) in wild-type (G) and HRasG12V/G12V (H) mice. The green square indicates layer VI of the primary 
somatosensory cortex barrel field (S1BF), an area chosen for cell size measurements (zoomed-in images). 
Zoomed-in pictures of layer VI of S1BF illustrates pyramidal neurons stained using DAPI (blue), NeuN (red) 
and FOXP2 (green; a marker for deep cortical layers in wild-type (G) and HRasG12V/G12V (H) mice. For (C–H) 
Data are presented as mean ± SEM from 4 hemispheres/2 mice per genotype. Statistical test: unpaired two-
tailed t-test, *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars G: 500 µm (left), (G) 20 µm (right).
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quadrants: t14 = −1.05, P = 0.16; between subject comparison F1,30 = 4.20, P < 0.05; Fig. 3B). After 4 additional 
days of training, mutants and wild-type mice reached the platform at comparable times (Fig. 3A), after which a 
probe trial confirmed that both wild-type and HRasG12V/G12V animals had learned to find the position of the plat-
form and showed selective spatial searching (TQ vs. OQ, HRasG12V/G12V: t14 = −4.64, P < 0.01; WT: t16 = −5,47, 
P < 0.01; between subject comparison, effect of genotype: F1,30 = 0.42, P = 0.79; Fig. 3C). These results indicate 
that HRasG12V/G12V mutant mice in the C57BL/6 background have a spatial learning impairment that can be over-
come with additional training.
In order to assess the cognitive flexibility of HRasG12V/G12V mice, the platform was then relocated to the oppo-
site quadrant for 5 additional training days, beginning on day 10. A probe trial on day 14 revealed that wild-type 
mice had successfully learned the new platform position (TQ vs. OQ: t9 = −3.89, P < 0.01), whereas HRasG12V/G12V  
mice again showed no preference for the target quadrant (TQ vs. OQ: t7 = −1.18, P = 0.14; between subject 
Phenotype
Mouse 
Model Costello Syndrome (CS)
Neurofibromatosis 
Type 1 (NF1) Noonan Syndrome (NS)10 Legius syndrome (LS)11
Gene HRAS NF1 PTPN11 SPRED1
Mutation HRASG12V/G12V NF+/− Ptpn11D61G/+ SPRED1−/−
pERK level Strongly increased# Moderately increased8, 24, 31 Moderately-strongly increased Normal-slightly increased
Behavior
Morris Water Maze Impaired#, 17 Impaired8, 24, 25, 31 Impaired Impaired
Contextual fear 
conditioning Normal
#, 1, 17 Impaired8, 24 Impaired
Rotarod Normal#, 17 Impaired25, 54 Normal
Neuronal function
LTP (TBS induced) Normal# Impaired ↓8, 24, 25, 31 Impaired ↓ Impaired ↓
LTD mGluR-LTD ↓# LFS-LTD ↑
Inhibitory function 
(s/m/eIPSCs)* Normal
# Increased8, 24, 25 Normal
Excitatory function (s/
mEPSCs) Normal
# Normal24, 25 Increased
I/O at strong stimulation Normal# Impaired8, 24 Normal Impaired
Short term/PPF Normal# Normal8, 25 Normal ↑
Ih current Normal25 ↓25
Brain morphology
Craniofacial features Abnormal#, 2 Normal8, 25 Abnormal52
Gross brain morphology Abnormal#; Normal39, **
Cell size/Cell number Increased#, 4/Increased39, *
Treatment: Lovastatin
Treatment 10 mg/kg, IP, adult mice, 3 days before the first training day, and then daily during behavioral training#, 9, 31
pERK level normalized? No Yes Yes
Behavioral deficit 
rescued? No Yes Yes
LTP rescued? (No phenotype) Yes Yes
Treatment: MEK-inhibitor
Drug PD0325901# PD03259019 SL327
Treatment
2 mg/kg, IP, adult mice, 
3 days before the first 
training day, and then 
daily during behavioral 
training
5 mg/kg, oral gavage, 
daily administration 
to lactating females 
for the treatment of 
P0.5– P18 mice
32 mg/kg, IP, adult mice, daily 
during behavioral training
pERK level normalized? Yes Yes9 Yes
Behavioral deficit 
rescued? No Yes
Brain morphology 
rescued? No Yes
9
Neuronal function 
rescued?
Yes (mGlur-LTD)# 
(U0126, 1 µM)
Yes (mIPSC)24, 
(U0126, 10 µM) Yes (LTP) (SL327, 1 µM)
Table 1. Overview and comparison of phenotypes and treatments in mouse models for four different 
RASopathies. Abbreviations: TBS – theta burst stimulation; LFS - low frequency stimulation, ↑ - significant 
increase; ↓ - significant decrease; Normal - no difference observed; “−” – no rescue observed; “+” – rescue 
observed; LTD – long-term depression; LTP – long-term potentiation; I/O – input/output; pERK – 
phosphorylated ERK; IP – Intra peritoneal injection; s-, m-, e E/IPSCs – spontaneous-, miniature- or evoked- 
excitatory (E)/inhibitory (I) postsynaptic currents; * - mIPSCs recordings in high KCl concentration (12,5 mM); 
** - young animals, E14-P7; #- current study.
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Figure 3. Learning impairment in HRasG12V/G12V mice in the Morris water maze (MWM). (A) Average latency 
to find the platform for each day of training. The first 9 days represent hidden platform MWM training for the 
initial platform position (platform position 1). On day 10, the reversal MWM protocol was started by changing 
the platform position (platform position 2). A decrease in the latencies of both genotypes can be observed, 
however on average HRasG12V/G12V mice took significantly more time to find the platform (between subject 
comparison day 1–9: F1,30 = 12.78, P < 0.01; day 10–14: F1,15 = 6.53, P < 0.05. (B) When spatial memory was 
assessed in a probe trial after 5 days of training, wild-type mice preferentially searched in the target quadrant 
(TQ, black bar) where the submerged platform had been during the training sessions (TQ vs. other quadrants: 
P < 0.01), whereas HRasG12V/G12V mice did not show a preference for the target quadrant (P = 0.15); between 
subject comparison: effect of genotype, P < 0.05). TQ = target quadrant, RQ = adjacent right quadrant, 
LQ = adjacent left quadrant, OQ = opposite quadrant. (C) A probe trial after four additional days of training 
showed that HRasG12V/G12V mice catch up with their WT littermates (TQ vs. other quadrants: HRasG12V/G12V: 
P < 0.01, WT: P < 0.01; between subject comparison: effect of genotype P = 0.79). Heat plots beneath the graphs 
provide a visual representation of all search tracks, in which the color indicates the mean time spent at a certain 
position in the pool. (D) After hidden-platform training mice were re-trained in a reversal MWM task. After 5 
days of training for a new platform position (day 10–14; platform position 2), wild-type mice but not HRasG12V/
G12V animals showed a preference for the TQ (TQ vs. other quadrants wild-type: P < 0.01; TQ vs. OQ HRasG12V/
G12V: P = 0.14; between subject comparison: effect of genotype P = 0.17). Data are presented as mean ± SEM 
from wild-type n = 17 mice, HRasG12V/G12V n = 15 mice (for A,B) and from wild-type n = 10 mice, HRasG12V/G12V 
n = 8 mice (for C). Statistical test: repeated measure one-way MANOVA, paired two-tailed t-test and one-way 
MANOVA. Arrows in A indicate day of probe trials.
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comparison: F1,16 = 2.01, P = 0.17; Fig. 3A,D). Therefore, we conclude that HRasG12V/G12V mice have reduced spa-
tial learning abilities, which may also impair cognitive flexibility (reversal MWM phenotype).
Baseline synaptic transmission and LTP are unaffected in HRasG12V/G12V mice. To determine 
whether changes in synaptic function account for the spatial learning impairments in HRasG12V/G12V mice, we 
measured baseline synaptic transmission using whole-cell recordings from hippocampal CA1 pyramidal neu-
rons. No significant differences were observed in the frequency or amplitude of spontaneous inhibitory or excit-
atory postsynaptic currents (sIPSCs: frequency: t44 = −0.39, P = 0.69; amplitude: t44 = 0.38, P = 0.70; sEPSCs, 
frequency: t44 = −0.32, P = 0.75; amplitude: t44 = 0.67, P = 0.50; Fig. 4A–D). Evoked monosynaptic IPSCs and 
EPSCs were also unchanged in HRasG12V/G12V mice compared to WT littermates (eEPSCs: F1,24 = 0.26, P = 0.61; 
eIPSCs: F1,19 = 0.01, P = 0.95; Fig. 4E–G).
The underlying mechanism for the cognitive deficits in the NF1 RASopathy mouse model has been previously 
shown to result from a shift in the excitatory/inhibitory balance, in which inhibitory synaptic transmission is 
abnormally enhanced during high frequency firing24, 25. Therefore, in order to investigate if a similar mechanism 
might be present in HRasG12V/G12V mice, we recorded spontaneous miniature inhibitory postsynaptic currents 
(mIPSCs) in the presence of depolarizing levels of extracellular potassium (increased from 2.5 to 12.5 mM KCl), 
as previously shown for Nf1 mice24, 25. As expected, high extracellular potassium (12.5 mM) resulted in a signif-
icantly increased frequency of mIPSCs in both HRasG12V/G12V and WT mice (frequency: F1,49 = 22.28, P < 0.05, 
amplitude: F1,49 = 1.21, P = 0.28; Fig. 4H,I). However, no differences in frequency or amplitude were observed 
between genotypes (effect of the genotype at 2.5 mM KCl condition frequency: F1,49 = 1.07, P = 0.30, amplitude: 
F1,49 = 0.56, P = 0.46; interaction genotype*12.5 mM KCl frequency: F1,49 = 0.38, P = 0.54, amplitude: F1,49 = 0.98, 
P = 0.33; Fig. 4H,I).
To further examine whether the HRasG12V/G12V mutation and the resulting increase of pERK signaling 
might affect short- or long-term forms of synaptic plasticity, we recorded field excitatory postsynaptic poten-
tials (fEPSPs) from hippocampal Schaffer collateral (SC)-CA1 synapses. Consistent with the whole-cell data, 
baseline synaptic transmission (defined by the relationship between the postsynaptic fEPSP slope and presyn-
aptic fiber volley amplitude) was similar between HRasG12V/G12V mice and their WT littermates (fiber volley: 
F1,53 = 0.15, P = 0.70, fEPSP slope: F1,53 = 17, P = 0.68; Fig. 5A). Furthermore, paired-pulse facilitation (PPF), 
which represents a presynaptically-mediated short-term form of plasticity, was also normal in HRasG12V/G12V 
mice (F1,14 = 0.36, P = 0.56, Fig. 5B). Since long-term plasticity (LTP) induced by theta-burst stimulation (TBS) 
is impaired in Nf18, 25, Ptpn1110, Spred1 mice11 and conditional KrasG12V mice26 (see Table 1), we tested LTP 
induced by a theta-burst stimulation protocol and a high frequency (100 Hz) stimulation protocol. Notably, 
both TBS-induced LTP and 100Hz-induced was similar between genotypes (TBS: F1,20 = 0.92, P = 0.51; 100 Hz: 
F1,14 = 0.80, P = 0.61; Fig. 5C,D). Taken together, these findings suggest that although constitutively active HRAS 
impairs spatial learning, it does not affect hippocampal synaptic transmission nor short- or long-term synaptic 
potentiation.
Impaired mGluR-LTD in HRasG12V/G12V mice. Metabotropic glutamate receptor-dependent long-term 
depression (mGluR-LTD), a form of synaptic plasticity resulting in decreased synaptic efficacy, has been shown 
to strongly depend on activity of the RAS-ERK pathway27, 28. Therefore, we hypothesized that hippocampal 
mGluR-dependent LTD might be affected in HRasG12V/G12V mice. Hippocampal slices from HRasG12V/G12V mice 
and their wild-type littermates were treated with DHPG (50 μM, 5 min), a specific agonist of group I (mGluR1 
and mGlur5) metabotropic glutamate receptors, to induce LTD. This resulted in a substantial initial depres-
sion of synaptic transmission in WT mice and significantly less pronounced depression in HRasG12V/G12V mice 
(F1,34 = 6.72, P < 0.05; Fig. 5E). This depression was followed by a robust long-lasting depression in fEPSCs 
amplitude in WT mice whereas it quickly returned to near baseline levels in HRasG12V/G12V mice, indicating that 
mGluR-dependent LTD cannot be stably expressed in HRasG12V/G12V mice (F1,34 = 13.29, P < 0.01; Fig. 5E). In 
order to determine the pathway and receptor specificity of the LTD deficit in HRasG12V/G12V mice, N-methyl 
D-aspartate receptor-dependent LTD (NMDAR-LTD) was induced using low-frequency stimulation (LFS). 
Notably, LFS-induced LTD was similar between HRasG12V/G12V mice and WT littermates (F1,26 = 0.40, P = 0.53; 
Fig. 5F), indicating that HRASG12V specifically affects mGluR-dependent LTD.
Lovastatin does not rescue the spatial learning deficit in HRasG12V/G12V mice. As shown in Fig. 1, 
a major biochemical alteration exhibited in HRasG12V/G12V mice is hyper activation of the RAS-ERK pathway, 
resulting from the constitutive activation of HRAS. The G12V mutation reduces the intrinsic GTPase activity 
of HRAS protein and thereby prolongs its GTP-bound state29, 30. Considering the fact that transition of GTD- 
to GTP-bound RAS relies on proper anchoring to the plasma membrane by means of a lipid (farnesyl)-based 
plasma-membrane-targeting motif, interfering with its membrane recruitment is an established strategy to reduce 
RAS activity. Notably, treatment with lovastatin, a specific inhibitor of the rate-limiting enzyme in cholesterol 
biosynthesis (HMG-CoA reductase), can reduce RAS farnesylation and activity, and has been previously shown 
to reverse spatial learning deficits in the Nf131 and Ptpn1110 mouse models for RASopathies. Therefore, we tested 
whether the same lovastatin treatment would also rescue the spatial learning deficit of HRasG12V/G12V mice. Mice 
were treated with lovastatin (10 mg/kg) once daily for 3 days prior to and during hidden platform Morris water 
maze training (daily injection 6 h prior to the training sessions). Although latencies to find the platform signifi-
cantly decreased in all groups during training (within-subjects comparison, effect of time: F1,58 = 46.80, P < 0.01), 
HRasG12V/G12V mice showed significantly longer latencies compared to wild-type littermates (between-subjects 
comparison, effect of genotype: F1,58 = 5.89, P < 0.05, Fig. 6A). Moreover, there was no effect of Lovastatin treat-
ment (genotype*treatment interaction: F1,58 = 0.23, P = 0.61). The effect of lovastatin on spatial learning in both 
groups was assessed in a probe trial given after the 7th day of the training. As shown in Fig. 6B, wild-type mice 
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Figure 4. Normal baseline synaptic transmission in wild-type mice. (A and C) Representative traces of whole-
cell patch-clamp recordings of spontaneous inhibitory (sIPSC) (A) and excitatory (sEPSC) (C) postsynaptic 
currents in acute hippocampal slices (B,D) Cumulative distribution of inter-event intervals (IEI; left panels) 
and amplitude (right panels) of sIPSCs and sEPSCs revealed no significant differences between the genotypes 
(sIPSCs: frequency: average: t44 = −0.39, P = 0.69, cumulative: P > 0.10; amplitude: average: t44 = 0.38, P = 0.70, 
cumulative: P > 0.10; wild-type n = 28 cells/7mice, HRasG12V/G12V n = 26 cells/5 mice) (sEPSCs: frequency: 
average: t44 = −0.32, P = 0.75, cumulative: P > 0.10; amplitude: average: t44 = 0.67, P = 0.50, cumulative: 
P > 0.10; wild-type n = 20 cells/5 mice, HRasG12V/G12V n = 26 cells/7 mice). Statistics: two-tailed t-test and 
Kolmogorov–Smirnov test (K–S) for average and cumulative values, respectively. (E–G) Evoked IPSCs and 
EPSCs are not altered in HRasG12V/G12V mice. (E) Representative traces of evoked EPSC (left) and IPSC (right) of 
wild-type cells (black trace) and HRasG12V/G12V cell (red trace). (F,G) Input-output curve representing averaged 
eIPSCs (wild-type n = 18 cells/10 mice, HRasG12V/G12V n = 14 cells/8 mice; (F) and eEPSCs (wild-type n = 19 
cells/9 mice, HRasG12V/G12V n = 20 cells/10 mice; G) Data are presented as mean ± SEM. Statistical test: repeated 
measure ANOVA: eEPSCs: F1,39 = 0.26, P = 0.61; eIPSCs: F1,32 = 0.01, P = 0.95. (H,I) Representative traces of 
whole-cell patch-clamp recordings of miniature inhibitory postsynaptic currents (mIPSC) in 2.5 and 12.5 mM 
KCl. A significant increase in the average frequency between 2.5 and 12.5 mM KCl was observed (F1,49 = 22,28, 
P < 0.01) but not in amplitude (F1,49 = 1,21, P = 0.28) nor between genotypes (genotypes: frequency: F1,49 = 1.07, 
P = 0.30, amplitude: F1,49 = 0.56, P = 0.46; interaction genotype*KCl: frequency: F1,49 = 0.38, P = 0.54, 
amplitude: F1,49 = 0.98, P = 0.33). (I) Cumulative distributions of IEI (left panels) and amplitude (right panels) 
of mIPSCs under 2.5 mM (upper panel) and 12.5 mM KCl condition (lower panel) showing no differences 
between genotypes at both conditions (2.5 mM KCl frequency: P > 0.10; amplitude; P > 0.10; wild-type n = 14 
cells/4 mice; HRasG12V/G12V n = 16 cells/5 mice) (12.5 mM KCl frequency: P > 0.10, amplitude: P > 0.10; wild-
type n = 10 slices/3 mice, HRasG12V/G12V n = 13 slices/4 mice). Statistical test: two-way MANOVA and K–S (for 
average and cumulative values, respectively).
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 1256  | DOI:10.1038/s41598-017-01218-0
treated with vehicle spent significantly more time searching in the target quadrant (TQ) than HRasG12V/G12V mice, 
confirming the impairment in spatial learning (TQ of HRasWT/WT vehicle vs. TQ of HRasG12V/G12 vehicle t27 = 2.18, 
P < 0.05). However, lovastatin did not improve spatial learning of either group (effect of treatment: F1,58 = 0.09, 
P = 0.76; genotype*treatment interaction: F1,58 = 0.07, P = 0.79; Fig. 6B).
To further characterise the effect of lovastatin treatment, we quantified pERK(42/44) in hippocampal lysates 
of WT and in HRasG12V/G12V mice following the completion of behavioural testing. As described above, pERK1/2 
level was significantly higher in HRasG12V/G12V mice compared to wild-type littermates (effect of the genotype: 
F1,10 = 6.48, P < 0.05), but unaffected by lovastatin treatment (effect of the treatment: F1,10 = 0.21, P = 0.65; interac-
tion genotype*treatment: F1,20 = 0.08, P = 0.78; Fig. 6C,D). Taken together, these data suggest that treatment with 
Figure 5. Normal long-term potentiation (LTP) but impaired mGluR-dependent long-term depression 
(LTD) in HRasG12V/G12V mice. (A) Field recordings of acute hippocampal slices revealed normal basal synaptic 
transmission in HRasG12V/G12V mice (effect of genotype: fiber volley: F1,53 = 0.15, P = 0.70, fEPSP slope: 
F1,53 = 0.17, p = 0.68). Data are presented as mean ± SEM from wild-type n = 29 slices/4 mice and HRasG12V/
G12V n = 26 slices/4 mice. (B) Paired-pulse ratio is not altered in HRasG12V/G12V mice compared to WT controls 
(F1,14 = 0.36, P = 0.56). Data are presented as mean ± SEM from: for 2.5 mM KCl: HRasWT/WT n = 25 slices/6 
mice, HRasG12V/G12V n = 26 slices/8 mice. (C-D) Normal LTP at Schaffer collateral-CA1 synapses in HRasG12V/
G12V induced by (C) theta burst stimulation (TBS, effect of genotype: F1,20 = 0.92, P = 0.51) or by (D) 100 Hz 
stimulation. Data are presented as mean ± SEM from for (C) wild-type n = 9 slices/4 mice, HRasG12V/G12V n = 13 
slices/4 mice n = 29 slices/4mice and for (D) wild-type n = 9 slices/4 mice, HRasG12V/G12V n = 7 slices/4 mice. 
(E) DHPG application (50 μM, 5 min) induced stable long-term depression (LTD) in WT mice. Impaired LTD 
was observed in HRasG12V/G12V mice (F1,34 = 13.29, P < 0.01). Data are presented as mean ± SEM from wild-type 
n = 20 slices/3 mice, HRasG12V/G12V n = 16 slices/3 mice. (F) NMDA receptor-dependent LTD, induced by low 
frequency stimulation (LFS), was indistinguishable between wild-type and HRasG12V/G12V mice (F1,26 = 0.40, 
P = 0.53). Data are presented as mean ± SEM from wild-type n = 17 slices/4 mice, HRasG12V/G12V n = 11 slices/3 
mice. Statistical test for (A–F): one-way repeated measures ANOVA. Data are expressed as percentage of the 
baseline prior to the stimulation protocol.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 1256  | DOI:10.1038/s41598-017-01218-0
lovastatin using the same dosing regimen that was sufficient to rescue special learning and pERK hyper-activation 
in the Nf131 and Ptpn1110 RASopathy models, is not effective in rescuing the spatial learning deficit of HRasG12V/
G12V mice.
Acute inhibition of MEK rescues deficit in mGluR-LTD in HRasG12V/G12V mice. Previous studies have 
demonstrated an important role of the RAS-ERK pathway in mediating the expression of mGluR-LTD27, 32. Hence 
we hypothesized that the mGluR-LTD deficit exhibited by HRasG12V/G12V mice might be caused by hyperactive 
ERK. If this model is valid, the impaired mGluR-LTD in HRasG12V/G12V slices should be able to be rescued by 
a MEK inhibitor, which would decrease ERK activation. Therefore, we induced mGluR-LTD by administering 
hippocampal slices with DHPG in addition to pre-treatment with either vehicle or a subthreshold dose of a 
selective and membrane-permeable MEK-inhibitor (U0126, 1 μM) which was previously shown not to affect 
WT mGluR-LTD at this concentration28. Application of DHPG induced stable depression of synaptic effi-
cacy in wild-type slices, but only a brief depression in HRasG12V/G12V slices treated with vehicle solution (effect 
Figure 6. Lovastatin does not rescue learning deficits or increased pERK level in HRasG12V/G12V mice. (A) 
Average latency to platform for each day of training, per genotype. A Significant effect of learning on the 
latencies of all groups was observed (within subject comparison: effect of time: F1,58 = 46.80, P < 0.01). On 
average, HRasG12V/G12V mice (both groups: lovastatin and vehicle treated) showed significantly longer latencies 
compared to wild-type littermates (between subjects comparison: effect of genotype: F1,58 = 5.89, P < 0.05). No 
effect of treatment on latencies was observed (between subjects comparison: effect of treatment: F1,58 = 0.23, 
P = 0.63). (B) Probe trial data of watermaze learning shows that lovastatin did not rescue the learning deficit 
in HRasG12V/G12V mice (effect of treatment: P = 0.76; genotype*treatment interaction P = 0.79). TQ = target 
quadrant, RQ = adjacent right quadrant, LQ = adjacent left quadrant, OQ = opposite quadrant. Heat plots 
represent all search tracks combined, in which the color indicates the mean time spent at that position in the 
pool. Data are presented as mean ± SEM. *P < 0.05. NS: Not significant. Number of mice: vehicle group wild-
type n = 17; HRasG12V/G12V n = 12; treated group: wild-type n = 17; HRasG12V/G12V n = 14. (C) Western blots of 
hippocampal lysates of the WT and HRasG12V/G12V mice showing an increased pERK level in untreated HRasG12V/
G12V mice, but no effect of lovastatin on pERK level. (D) Quantification of Western blots. A significant effect 
of genotype was found in pERK level (F1,20 = 6.48, P < 0.05). No main effect of treatment on pERK could be 
detected (F1,20 = 0.21, P = 0.65; interaction genotype*treatment: F1,20 = 0.08, P = 0.78). Data are presented as 
mean ± SEM normalized to vehicle group wild-type. n = 5; HRasG12V/G12V n = 5; treated group: wild-type n = 7; 
HRasG12V/G12V n = 7. Three mice per group are depicted in the example blot. Statistical test: two-way MANOVA.
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of genotype, vehicle treated group: F3,63 = 8.53 P < 0.01; Fig. 7), thereby replicating the mGluR-LTD deficit in 
HRasG12V/G12V mice. Notably, pre-incubation of slices with the MEK-inhibitor U0126 rescued the LTD deficit in 
HRasG12V/G12V (WT vehicle vs. HRasG12V/G12V treated, Bonferroni’s post-hoc test P < 0.05) without any discernible 
effect on LTD in WT littermates (WT vehicle vs. WT treated, Bonferroni’s post-hoc test P > 0.05). Together, these 
results indicate that the deficit in mGluR-LTD observed in HRasG12V/G12V mice is indeed caused by hyperactive 
RAS-ERK signaling, and that acute inhibition of this pathway with a MEK inhibitor restores normal induction 
and expression of mGluR-LTD in HRasG12V/G12V mice.
Restoring pERK levels in HRasG12V/G12V mice by a MEK inhibitor does not rescue the spatial 
learning deficit or increased brain weight. Given that the mGluR-LTD deficit of HRasG12V/G12V slices 
can be rescued by a MEK inhibitor, we investigated whether the learning phenotype observed in HRasG12V/G12V 
could be reversed by treatment with a MEK inhibitor. For these experiments, we used the allosteric MEK inhib-
itor PD0325901 which has good bioavailability and is often used for in vivo studies, including studies targeting 
the brain9, 33–35. Although previous studies have shown a rescue of several phenotypes in an adult mouse model of 
Noonan syndrome using PD0325901 at 5 mg/kg bodyweight35, we sought to identify a lower effective dose, since 
inhibition of the RAS-ERK pathway results in learning deficits36. Mice were injected daily for 7 days with 2 or 
5 mg/kg of PD0325901 and sacrificed 2 h after their final scheduled injection to assess pERK levels. As shown in 
Fig. 8A,B, pERK was significantly higher in vehicle-treated HRasG12V/G12V mice compared to vehicle treated WT 
littermates. Treatment with the MEK-inhibitor showed a dose-dependent effect on pERK in both HRasG12V/G12V 
mice as well as wild-type littermates (effect of genotype: F1,34 = 6.88, P < 0.05). At only 2 mg/kg of PD0325901, a 
significant effect of treatment was already observed (F1,34 = 38.95, P < 0.01), in which pERK levels in HRasG12V/
G12V mice were similar to vehicle-treated wild-type littermates. Hence, we chose to proceed with the 2 mg/kg daily 
dose, beginning 3 days prior to water maze training. All groups of mice showed a significant reduction in the 
latency to find the platform during training (effect of time: F1,55 = 49.50, P < 0.01). However, HRasG12V/G12V mice 
exhibited significantly longer search latencies, regardless of treatment (effect of genotype: F1,55 = 8.97, P < 0.01; 
Fig. 8C).
Spatial learning of wild-type and HRasG12V/G12V littermates, treated either with vehicle or PD0325901, was 
assessed in a probe trial after 5 days of training, a time point in which the wild-type mice showed already a strong 
preference for the target quadrant. Although it was notable that under these conditions vehicle treated HRasG12V/
G12V mice also showed a significant preference for the target quadrant, we again observed a significant effect of 
genotype with respect to time spent in the target quadrant, replicating the spatial learning deficit in HRasG12V/G12V 
mice (effect of genotype: F1,51 = 6.07, P < 0.05; Fig. 8D). In addittion, a significant effect of treatment was observed 
this time (F1,51 = 7.41 P < 0.05; Fig. 7D), but this was mediated by a decrease in performance of the treated mice. 
There was no significant interaction between genotype and treatment (F1,51 = 1.21, P = 0.28).
In order to confirm that daily PD0325901 treatment reduced pERK levels in HRasG12V/G12V mice to that of their 
wild-type littermates, we performed Western blot analysis of hippocampal lysates taken from WT and HRasG12V/G12V  
mice immediately following the conclusion of the probe trial. Quantification of Western blots revealed a signif-
icantly higher level of pERK in vehicle-treated HRasG12V/G12V mice compared to vehicle treated wild-type mice 
(effect of genotype F1,37 = 47.83, P < 0.01) with a significant decrease in pERK after PD0325901 treatment in 
both WT and HRasG12V/G12V mice (effect of treatment F1,37 = 35.49, P < 0.01; genotype*treatment F1,37 = 0.81, 
Figure 7. Acute inhibition of MEK rescues deficit in mGluR-LTD in HRasG12V/G12V mice. Induction of chemical 
LTD by application of DHPG for 5 min (50 μM), induced stable depression of synaptic efficacy in slices of WT 
and only temporarily depression in HRasG12V/G12V slices, both treated with vehicle solution (effect of genotype, 
vehicle treated group: F3,63 = 8.53, P < 0.01). Pre-incubation of slices with a MEK-inhibitor, U0126, did not 
affect wild-type LTD (wild-type vehicle vs. wild-type treated, P > 0.05), but rescued the LTD-deficit in HRasG12V/
G12V (wild-type treated vs. HRasG12V/G12V treated, p < 0.05). Data are presented as mean ± SEM from vehicle 
treated wild-type. Vehicle treated: wild-type n = 17 slices/5 mice, HRasG12V/G12V n = 17 slices/5 mice and drug 
treated: wild-type n = 16 slices/4 mice, HRasG12V/G12V n = 20 slices/5 mice. Statistical test: repeated measure 
ANOVA and post-hoc Bonferroni correction.
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Figure 8. Inhibition of MEK with PD0325901 restores pERK levels but does not rescue the spatial learning 
deficit. (A) Western blots of hippocampal lysates of WT and HRasG12V/G12V mice treated with vehicle, 2 and 
5 mg/kg of PD0325901. (B) Quantification of Western blots showing that both doses used affect pERK levels in 
both wild-type and HRasG12V/G12V mice. For both 2 and 5 mg/kg: effect of genotype: P < 0.01, effect of treatment: 
P < 0.01, interaction genotype*treatment P < 0.01. Data are presented as mean ± SEM from 6 mice per group. 
Two mice per group are depicted in the example blot. Statistical test: two-way ANOVA. (C) Average latency 
to platform for each day of training, per genotype. On average longer latencies were observed in vehicle and 
PD0325901 drug treated HRasG12V/G12V mice (effect of genotype P < 0.01). (D) Spatial memory assessed in 
a probe trial reveals a significant effect of genotype (P < 0.05) on time spent in the target quadrant (TQ). 
Although PD0325901 significantly reduced performance of wild-type mice, it showed no effect on mutant mice 
and no interaction of genotype and treatment was observed (P = 0.28). TQ = target quadrant, RQ = adjacent 
right quadrant, LQ = adjacent left quadrant, OQ = opposite quadrant. Heat plots present the data of all tracks 
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P = 0.38; Fig. 8E,F). Importantly, pERK levels in PD0325901-treated HRasG12V/G12V mice were similar to their 
vehicle-treated WT littermates, and thus reduced to normal levels.
We also examined whether PD0325901 treatment influenced the brain weight of WT and HRasG12V/G12V mice. 
HRasG12V/G12V mice again exhibited significantly heavier brains, independent of body weight (effect of geno-
type: brain weight: F1,12 = 28.20, P < 0.01; body weight: F1,12 = 0.05, P = 0.83). However, we observed no effect of 
PD0325901 treatment (effect of genotype: brain weight: F1,12 = 0.45, P = 0.84, body weight: F1,12 = 0.01, P = 0.91; 
interaction genotype*treatment: brain weight: F1,12 = 0.65, P = 0.43; body weight: F1,12 = 0.00, P = 1.00; Fig. 9). 
Taken together, these data suggest that although acute MEK inhibition with PD0325901 successfully restores the 
level of pERK in adult HRasG12V/G12V mice to that of WT mice, the MEK inhibitor does not rescue the morpholog-
ical alterations or spatial learning deficits under these conditions.
Discussion
Here we report that a mouse model for Costello syndrome (CS), which carries an activating mutation in the 
HRAS gene, shows hyperactivation of the RAS-ERK pathway, learning deficits, structural brain abnormalities, 
and alterations in synaptic functioning. Although we studied homozygous HRasG12V/G12V mice, these mice express 
the HRASG12V protein at approximately 50%, and hence their levels of oncogenic HRAS protein resemble that of 
heterozygous CS patients. The reduced HRAS protein expression is possibly caused by the IRES-β-geo cassette 
inserted into the 3′UTR of the HRasG12V targeting vector, as reduced expression is not observed in an independent 
line of HRasG12V mice37.
Previously it has been shown that pERK was not increased in this mouse line16, 17, whereas we consist-
ently observed a highly significant increase in pERK levels in hippocampal lysates (Fig. 1). This could be due 
to brain-region specific variability of ERK expression and activation levels resulting in no significant difference 
observed in total brain lysates38. Indeed, immunolabeling as shown by Viosca et al. clearly indicate increased pERK 
staining in CA3 mossy fiber region of hippocampus suggesting that, at least, locally pERK levels are enhanced.
We have deliberately focused our study on CS, as the RAS protein is the central protein of the RAS-ERK 
signaling pathway. In contrast to germline KRASG12V mutants, the germline HRasG12V mutation is not lethal, 
which allowed us to directly study the molecular, cellular, and behavioral consequences of a constitutively active 
HRAS protein present from germline. Furthermore, it also enabled us to determine if there were differences 
in phenotype- or treatment efficacy compared to other mouse models of RASopathies caused by mutations in 
up-stream regulators of HRAS protein, such as NF1, SHP2/PTPN11, and SPRED1.
In accordance with several previous studies using adult transgenic HRasG12V overexpressing mice, we observed 
brain and neuronal hypertrophy in HRasG12V/G12V mutant mice20, 21. Moreover, an enlarged corpus callosum was 
observed after bi-allelic inactivation of Nf19. These morphological changes could not be rescued by acute treat-
ment with the MEK-inhibitor PD0325901 during adulthood. A recent study reported that aberrant RAS signaling 
in the developing brain (E14-P7) resulted in an increased production of cortical neurons and morphological 
deficits39. In addition, other studies have demonstrated a clear requirement for intact ERK activity in controlling 
cortical development, including fibroblast growth factor (FGF)-stimulated cortical progenitor differentiation and 
neurogenesis2, 40. Moreover, a recent study showed increased proteoglycan expression in astrocytes derived from 
iPSCs from CS patients as well as in astrocytes of mutant HRasG12S mice41. These studies highlight the importance 
of proper control of the RAS-ERK signaling during brain development, and suggest that adult treatment could be 
too late to restore the behavioural phenotype.
As summarized in Table 1, mouse models for Costello Syndrome (CS), Neurofibromatosis I (NF1), Noonan 
Syndrome (NS), and Legius Syndrome show similar phenotypes including hyperactivity of the RAS-ERK 
pathway, learning deficits in the water maze, and impaired synaptic plasticity, which confirm the widespread 
observation of overlapping disease manifestations across patients with different RASopathies. Given the shared 
biochemical alteration of increased hyperactivity of the RAS-ERK pathway, and the indisputable role of RAS-ERK 
signaling in LTP and memory formation36, 42, it seemed reasonable to assume that the plasticity deficits observed 
in these RASopathy mouse models might all be caused by the same mechanism. However, a closer look at the 
specific cellular mechanisms reveals substantial differences between the RASopathy mouse models. For instance, 
neither the cell-type specific increase of inhibition found in Nf1 mutants24 and a conditional KrasG12V mutant26, 
nor the increase of glutamatergic synaptic transmission observed in the NS model10 were observed in HRasG12V/
G12V mice. In addition, we and others showed that LTP induced by theta-burst stimulation is impaired in all 
RASopathy mouse models published so far: Nf18, 25, Ptpn1110, Spred1 mice11 and conditional KrasG12V mice26. 
However, despite the strong ERK activation, LTP was unaffected in HRasG12V/G12V mice. The phenotypic differ-
ences between the mutants could be caused by differences in RAS-ERK activation (Table 1), by differences in 
cell-type specific expression, and/or by differential regulation during development. These possibilities could also 
explain increased LTP in transgenic mice expressing the same HRAS protein (HRASG12V) driven by the CAMK2 
promoter43 resulting in transgenic expression restricted to glutamatergic pyramidal neurons in the cortex and 
combined, in which the color indicates the mean time spent at that position in the pool. Data are presented as 
mean ± SEM from: vehicle group: wild-type n = 14 mice; HRasG12V/G12V n = 14 mice; treated group: wild-type 
n = 13 mice; HRasG12V/G12V n = 13 mice. Statistical test: repeated measures two-way ANOVA and two-way 
MANOVA, respectively. (E) Western blot of hippocampal tissue taken from WT and HRasG12V/G12V mice after 
water maze training and concurrent treatment with either vehicle or PD0325901. (F) Quantification of Western 
blots. A significant effect of genotype (F1,37 = 47.83 P < 0.01) and treatment (P < 0.01) on pERK was observed. 
No interaction effect of genotype and treatment was found (P = 0.37). Data are presented as mean ± SEM from 
n = 10 mice per group. Statistical test: unpaired two-tailed t-test.
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hippocampus. Moreover, there could be subtle differences in the intracellular location of HRAS, NF1, SPRED1, 
PTPN11 and KRAS which diverge in their relative subcellular signaling mechanisms44, 45. Lastly, some of these 
proteins may have RAS-independent functions. For example, it was recently reported that NF1 interacts with 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels for which mutations in Nf1 cause attenua-
tions of Ih current selectively in GABAergic interneurons25. Treatment with the HCN channel agonist lamotrig-
ine during adulthood rescued the cognitive deficits in two different Nf1 mouse models, thereby establishing an 
important function of HCN channels in mediating the NF1 phenotype. In contrast, HCN function is unaffected 
in HRasG12V/G12V mice25.
Previous studies have shown that mGluR-dependent LTD is sensitive to changes in ERK activity. High con-
centrations of the MEK-inhibitor U0126 (20 µM) impair mGluR-LTD27, 28, while a lower dose of U0126 (1 µM), 
which did not affect mGluR-LTD in WT mice, was sufficient to rescue the mGluR-LTD deficit in HRasG12V/G12V 
mice. This counter-intuitive result suggests that mGluR-LTD is sensitive to both hypo- and hyper activation of 
RAS-ERK pathway. Possibly, due to the high levels of RAS-ERK signaling in our mouse model, mGluR-mediated 
LTD was inhibited, and pre-treatment with a low dose of U0126 brought ERK signaling back into the normal 
range. To determine the mechanism underlying the impairment of mGluR-LTD in HRasG12V/G12V mice will 
require further investigation. In addition, it will be important to assess whether mGluR-LTD is altered the NF1, 
Legius Syndrome, or Noonan syndrome RASopathy mouse models.
Until recently, many symptoms of neurodevelopmental disorders, including RASopathies and mTOR-pathies3, 
were thought to be untreatable in adulthood due to their neurodevelopmental alterations, including gross brain 
dysmorphology and/or neuronal wiring/connectivity. Remarkably, candidate therapies implemented in NF1 and 
Noonan syndrome mouse models have shown extensive phenotypic rescue, including behavioral, synaptic, and 
molecular alterations. For instance, spatial learning deficits in adult Nf1+/− mice were rescued by treatment with 
farnesyl-transferase inhibitor (FTI), which reduces RAS activity by interfering with the farnesylation of RAS, a 
post-translational modification that allows RAS to be targeted to the membrane8, 46. Moreover, a behavioral res-
cue was shown after treatment of adult Nf1+/− and Ptpn11D61G/+ mice for 3–4 weeks with lovastatin, which affects 
the synthesis of farnesyl10, 31. Furthermore, lovastatin reduced pERK levels in Nf1+/− and Ptpn11D61G/+ mice, and 
reduced pERK-dependent protein synthesis in the mouse model of Fragile X Syndrome, indicating its potency in 
restoring alterations of the RAS-ERK pathway10, 31, 47. Unfortunately however, we found that implementation of 
the identical lovastatin treatment regimen was unable rescue learning deficits and pERK levels in adult HRasG12V/
G12V mice (Fig. 6). It is likely that the G12V mutation, leads to much higher activation of the RAS-ERK pathway 
than mutations in upstream regulators of RAS protein, such as NF1 or PTPN11/SHP2 and therefore might be less 
responsive to lovastatin. In support of this, extensive studies of the effects of lovastatin as a potential cancer ther-
apy have revealed that the concentration of statins required to significantly reduce farnesylation of RAS proteins 
with oncogenic mutations such as G12V are impossible to achieve in vivo without substantial side effects48, 49.
A recent study has shown that the MEK inhibitor SL327 restored learning, LTP, and ERK signaling in adult 
mouse models for Noonan Syndrome, caused by mutations in PTPN1110 (Table 1). Surprisingly, even though we 
observed that the mGluR-LTD deficit in HRasG12V/G12V mice can be rescued by a lower concentration of MEK 
inhibitor, treatment of HRasG12V/G12V mice with 2 mg/kg of PD0325901 (a MEK-inhibitor which has good bio-
availability and is currently in clinical trials)9, 33–35 successfully restored pERK levels but was insufficient to rescue 
the spatial learning impairment. Recently, it was also shown that treating adult conditional KRasG12V mice with 
PD0325901 failed to rescue the behavioural phenotype26. There are several possible explanations for our failure 
to rescue the behavioural phenotype of HRasG12V/G12V mice. First, although we chose a dose that resulted in a 
normalization of pERK levels, it may be possible that we have not used an optimal dose. Second, it might be that 
Figure 9. Treatment with MEK inhibitor does not reduce the increased brain weight of HRasG12V/G12V mice. (A) 
Daily treatment with 2 mg/kg of PD0325901 for 4 weeks does not reduce the increased brain weight observed 
in HRasG12V/G12V mice (effect of genotype: brain weight: F1,12 = 28.20, P < 0.01; body weight: F1,12 = 0.05, 
P = 0.83; effect of treatment: brain weight: F1,12 = 0.45, P = 0.84, body weight: F1,12 = 0.01, P = 0.91; interaction 
genotype*treatment: brain weight: F1,12 = 0.65, P = 0.43; body weight: F1,12 = 0.00, P = 1.00). Data are presented 
as individual values of brain vs. body weight from n = 4 mice per each group. Statistical test: two-way 
MANOVA.
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the observed morphological brain abnormalities interfere with normal learning, despite acutely normalized levels 
of RAS-ERK signaling. Lastly, it could be that successful rescue of the learning deficit of HRasG12V/G12V mice with 
lovastatin or MEK inhibitors requires treatment earlier in neurodevelopment. We recently demonstrated that 
adult gene-reactivation in a mouse model for Angelman Syndrome rescued LTP but not the cognitive and motor 
impairments, while early developmental gene reactivation led to a full rescue of all phenotypes, thereby suggest-
ing a therapeutic critical period for achieving effective treatment in certain neurodevelopmental disorders50.
Our findings in the HRasG12V/G12V mouse model, as well as emerging findings in the NF1 and Noonan syn-
drome mouse models10, 25, suggest that the mechanisms underlying learning deficits in RASopathies can be highly 
distinct, for which a universal treatment effective across all RASopathies remains elusive. Further studies are 
required to uncover the additional mechanisms underlying this divergence, and to identify the most optimal 
therapeutic strategies.
Materials and Methods
Animals. Mice used for this study were previously described and generously provided by Mariano Barbacid 
and co-workers16. These animals express a G → T missense mutation in the second base of the twelfth codon 
of the endogenous HRAS gene locus, which replaces the normal GGA (glycine) sequence with GTA (valine) 
causing a constitutively active, GTP-bound HRASG12V protein. In order to be able to monitor HRAS expression, 
an internal ribosomal entry site–β-gal–neomycin resistance fusion protein (IRES–β-geo) cassette was inserted 
into the 3′ UTR of the HRAS gene. This allows visualization of HRAS gene expression patterns, by histological 
X-gal staining methods. HRas+/G12V mice were backcrossed (20–25 crosses) and maintained in the C57BL/6J 
background, and were intercrossed to generate homozygous (HRasG12V/G12V), heterozygous (HRasG12V/WT), and 
wild-type (HRasWT/WT) littermates. All experiments were performed with HRasWT/WT and HRasG12V/G12 mice, as 
more robust neurological deficits were found among homozygous HRasG12V/G12 mice than in the analysis of het-
erozygous HRasG12V/WT mice, suggesting the existence of a gene dose effect17. Both males and females mice were 
used in all experiments.
All mice were between 8 and 14 weeks of age at the start of the behavioral experiments, housed in groups of 
2–4 per cage, on a regular 12 h light/dark cycle (lights on between 7:00 am and 7:00 pm), and fed standard labora-
tory food ad libitum. Experimenters were blind to genotype and treatment. All experiments were approved by the 
Dutch Ethical Committee (DEC) and were in accordance with the institutional animal care and use committee 
guidelines.
Western blot. To obtain hippocampal tissue, animals were anesthetized with isoflurane after which they were 
decapitated and tissue was quickly isolated. Tissue was homogenized in 0.1 M Tris-HCl (pH 6,8), 4% SDS sup-
plemented with protease and phosphatase inhibitor cocktails (Sigma). The concentration of protein was adjusted 
to 1 μg/μl. 15 μg was used for Western blot analysis using 18-wells Criterion XT Bis-Tris precast gels (Bio-Rad). 
When using 26-wells gels, 10 μg protein was loaded. Primary antibodies used were HRAS (HRAS (C20), Santa 
Cruz Biotechnology), ERK (p44/42 MAPK, Cell Signaling), phospho-ERK (Ph-p44/42 MAPK, Cell Signaling). 
Actin was always included as a loading control (Actin, Millipore). Blots were probed with IR Dye secondary 
antibodies (IR Dye 680LT or 800CW, LI-COR) and visualized using LI-COR Odyssey infrared imager. For quan-
titative analysis, Odyssey V3.0 software was used.
Immunohistochemistry. Mice were deeply anesthetized with pentobarbital and perfused transcardially 
with Phosphate Buffered Saline (PBS) followed by freshly prepared 4% paraformaldehyde (PFA, Sigma). Brains 
were carefully removed and fixed for two hours in 4% PFA, followed by 24 h incubation in 0.1 M phosphate buffer 
(PB) and 10% sucrose. Brains were then embedded in gelatine blocks (10% gelatine, 10% sucrose), post-fixed in 
10% formaldehyde and 30% sucrose for 3 h, and kept in 30% sucrose overnight at 4 °C. The embedded brains were 
sectioned coronally using a freezing microtome with a section thickness of 40 μm and collected in PBS. Sections 
were stained with Cytochrome C or thionin, processed for LacZ staining (to visualize the expression of the HRAS 
gene mutation), or processed for immunohistochemistry. LacZ staining was performed by overnight incubation 
in 1 ml X-gal solution containing: 5% X-gal, 5 mM K3F3(CN)6, 5 mM K4F3(CN)6.3H2O, 2 mM MgCl2, 0.01% 
Nadeoxycholate, 0.02% NP40 in PBS. In cases where X-gal treatment was combined with immunohistochemistry, 
X-gal incubation preceded the other immunohistochemical steps.
For immunohistochemistry, sections were pretreated with 10 mM Na-citrate for 2 hours in 80 °C to facil-
itate binding of antibodies and to minimize variability introduced by the quality of perfusion. Following the 
blocking step, sections were incubated in primary antibody for 2 nights at 4 °C. Primary antibodies used are 
HRAS (HRAS (C20), Santa Cruz Biotechnology), phospho-ERK (p44/42 MAPK, Cell Signaling), ERK (p44/42 
MAPK, Cell Signaling), anti-NeuN (Millipore MAB377, 1:2,000), goat anti-FoxP2 (AbCam, 1:1,000). Secondary 
antibodies used for confocal microscopy include FITC-conjugated donkey-anti-rabbit and Cy3-conjugated 
donkey-anti-sheep (Jackson Immuno Research Laboratories). DAPI (P36931, Life Technology) was used for 
nuclear staining. Sections stained for immunofluorescence were analyzed with Zeiss (Oberkochen, Germany) 
LSM700 confocal laser scanning microscope using 10x/0.45, 20x/0.8 numerical aperture objective and 40x/1.3 
(oil-immersion) objectives. For immunohistochemistry, an avidin-biotin–immunoperoxidase complex method 
(ABC; Vector Laboratories) with diaminobenzidine (0.05%) as the chromogen and biotinylated secondary anti-
bodies (Jackson ImmunoResearch) were used. Immunoperoxidase-stained sections were analyzed and pho-
tographed using a Leica DM-RB microscope and a Leica DC300 digital camera (Leica Microsystems GmbH, 
Wetzlar, Germany).
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Neuroanatomical measurements. Mice were transcardially perfused with freshly prepared 4% PFA and 
the brain was carefully taken out of the skull, after which the weight, height, length and width of the brain was 
immediately measured using a microscale (Sartorius AG, Germany) and a digital calliper (Mitutoyo Ltd., UK).
For quantititave analysis of neuronal sizes transverse serial sections were stained for cytochrome C or thionin 
or DAPI, NeuN, and Fox2 immunofluorescence following the procedures described above. Cross-sectional sur-
face areas and thickness were determined using the ImageJ image analysis system. Measurements were made 
in matched cytochrome C-stained coronal sections (40 um thick) of WT and HRasG12V/G12V littermates. Cross 
sections at 3 different levels were analysed: coordinates to Bregma: 0.50 mm (Plate27), 0.02 mm (plate 31) and 
−0.46 mm (plate 35) according to the Paxinos and Franklin mouse brain atlas53. The contours of each measured 
cortical and corpus callosum (CC) area were traced using a manually driven cursor (Fig. 2C). Areas were cal-
culated from the digitized data derived from a series of six sections per animal (three sections per hemisphere). 
Corpus callosum (CC) thickness was determined at the midline whereas thickness of the cortex was measured 
above the highest edge of lateral ventricle (Fig. 2C, black line in the left cortex hemisphere). The data were evalu-
ated by unpaired t-tests to determine whether there were significant differences between genotypes.
ImageJ software was used for the analysis of cell size. Images and z-stacks were collected on a Zeiss LSM 710 
confocal microscope with 10x and 40x objectives (zoom factors 1 and 0.50) from the somatosensory cortex S1 
(Fig. 2F). Z-stacks were collected from cortical laminas II/III, IV/V, and VI. Each z-stack contained between 
17–32 images collected with 40x objective (zoom factor 1). From each z-stack, 3 images were randomly identified 
for cell size analysis, without overlap between the selected images. The number of DAPI positive/NeuN negative, 
NeuN positive, and FoxP2 positive/NeuN positive cells were determined for each image. Cells were selected for 
size/area measurement according the following criteria: 1) full nucleus visible in the selected plane (DAPI), 2) 
cell positive for NeuN, 3) cell fully visible. An average of 20 cells per image were analysed. Contours of cells were 
traced manually using the Freehand selection tool of ImageJ to create regions of interest (ROI), which were sub-
sequently analysed and saved using the ROI Manager tool of ImageJ.
Behavioral assessment. One week long before the start of the behavioral testing, all mice were habitu-
ated to the experimentator and handling to reduce stress during experiments. For assessment of spatial learning, 
the Morris Water Maze (MWM) task was used as previously described51. Mice were handled for one minute 
per day, beginning one week prior to the experiment. Our water maze is a circular pool with a diameter of 1.2 
meters, filled with an opaque mixture of water and white paint. Water temperature was maintained between 
25–26 degrees Celsius. The escape platform has a diameter of 11 cm and is submerged 1 cm beneath the water 
surface. Visually-salient and readily-distinguishable distal cues were displayed on each wall of the room. Mice 
were trained using two 60 s trials per day, with a 30 s inter-trial interval, for five consecutive days. During training, 
mice were placed on the platform for 30 s and subsequently placed into the pool at pseudo-random starting posi-
tions. After reaching the platform, the mice were allowed to remain for 30 s, before returning to their home cage. 
If a mouse was unable to locate the platform within 60 s, the trial was concluded and the mouse was gently placed 
on the platform by the experimenter, and remained there for 30 s. The platform location was in a fixed position 
throughout all trials. For each trial, latency, distance covered, mean swim speed, and search path were measured.
Probe trials were initiated when average latencies dropped below 30 s and a significant number of mice showed 
selective searching. During the probe trial, the platform was removed from the pool. The mice were placed in the 
pool at the opposite side where the platform used to be and allowed to search for 60 s. The amount of time spent 
in each quadrant, and platform location crossings, were measured for each probe trial. For statistical analysis, 
the time in the target quadrant was compared to the average of the other three quadrants. Next, the platform was 
switched to another location (reversal-learning paradigm) and mice were retrained for 5 days after which mem-
ory was assessed by means of another probe trial (day 14).
Drug treatment. Lovastatin: The HMG-CoA reductase inhibitor lovastatin was purchased from Sigma, 
stored according to the manufacturer’s instructions, and freshly dissolved as previously described31. The solution 
was administered by subcutaneous (SC) injection of 10 mg/kg (body weight) daily.
MEK inhibitor (PD0325901; Sigma-Aldrich) was dissolved in DMSO at a concentration of 25 mg/ml and 
resuspended in vehicle (0.5% hydroxypropyl methyl-cellulose with 0.2% Tween 80; Sigma-Aldrich) at a concen-
tration of 1 mg/ml as described by9. The solution was administered by intraperitoneal injection (IP) of 2 mg/kg or 
5 mg/kg (body weight) daily.
Lovastatin (10 mg/kg; SC), PD0325901 (2 mg/kg; IP), or vehicle (DMSO with 0.5% hydroxypropyl 
methyl-cellulose and 0.2% Tween 80) was injected once daily for 3 d prior to, and during, Morris water maze 
training 6 h prior to training. As described above, mice were trained in the hidden version of the MWM for 7 days 
(2 trials/day) after which the probe trial was given.
Electrophysiology. Field and whole-cell patch-clamp recordings were performed as previously described25. 
Briefly, hippocampal slices were prepared from mice (3 to 4 week-old for whole cell recording, 3 to 6 week-old 
for LTD, and 3–6 week-old as well as 8–20 weeks old for LTP recordings). Mice were decapitated under deep iso-
flurane anesthesia, brains quickly removed and placed in ice-cold modified artificial cerebrospinal fluid (ACSF) 
containing (in mM): 3 KCl, 1.3 CaCl2, 2.5 MgSO4, 1.25 NaH2PO4, 10 glucose, 26 NaHCO3, and 212.3 sucrose 
oxygenated with 95% O2 and 5% CO2 (pH 7.3–7.4). For the whole-cell recordings transverse hippocampal slices 
(300 μm) were cut in ice-cold modified ACSF using a vibratome (HM650V; Microm). Slices were then stored in 
a holding chamber containing standard ACSF (in mM): 126 NaCl, 3 KCl, 2 MgSO4, 2 CaCl2, 10 glucose, 1.25 
NaH2PO4, and 26 NaHCO3 bubbled with 95% O2 and 5% CO2 (pH 7.3) at room temperature for at least 1 h. 
Individual slices were transferred to the submerged recording chamber perfused with standard ACSF continu-
ously bubbled with 95% O2 and 5% CO2 at 30–32 °C.
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Whole-cell patch-clamp recordings were performed from hippocampal CA1 pyramidal neurons visualized 
with a Zeiss microscope using infrared video microscopy and differential interference contrast (DIC) optics. Patch 
electrodes were pulled from borosilicate glass capillaries and had a resistance of 3–5 MΩ when filled with intra-
cellular solutions. Inhibitory synaptic responses were evoked using twisted platinum/iridium electrodes placed 
100–150 μm from the recording site. Spontaneous inhibitory synaptic currents (IPSCs) were recorded in the 
presence of 6-cyano-7- nitroquinoxaline-2,3-dione (CNQX) (10 μM) and D,L-2-amino-5-phosphopentanoic acid 
(D,L-AP5) (20 μM) with internal solution containing (in mM): 70 K-gluconate, 70 KCl, 10 HEPES, 0.5 EGTA, 4 
MgATP, 0.4 Na2GTP, 4 phosphocreatine (pH 7.3 with KOH) or 125 CsCl, 2 MgCl2, 5 NaCl, 10 HEPES, 0.2 EGTA, 
4 MgATP, 0.4 Na2GTP (pH 7.3 with CsOH). Spontaneous excitatory synaptic currents (EPSCs) were recorded in 
the presence of picrotoxin (100 μM) and with internal solution containing (in mM): 140 K-gluconate, 1 KCl, 10 
HEPES, 0.5 EGTA, 4 MgATP, 0.4 Na2GTP, 4 phosphocreatine (pH 7.3 with KOH). Miniature IPSCs/EPSCs were 
recorded in the presence of 1 μM TTX. Recordings were made with a patch-clamp amplifier (Multiclamp 700B; 
Axon Instruments, Foster City, CA, USA). Signals were low-pass filtered at 2–4 KHz and digitized at 10 KHz. 
Series resistance was constantly monitored, and the cells were rejected from analysis if the resistance changed 
by >15%. No series resistance compensation was used. Only cells with stable resting membrane potential and 
overshooting action potentials with stable amplitude were included in the study. Resting membrane potential was 
measured in bridge mode (I = 0) immediately after obtaining whole-cell access.
Field EPSP recordings were performed as previously described25, 52. Briefly, field excitatory postsynaptic poten-
tials (fEPSPs) were evoked by stimulating the Schaffer collateral/commissural pathway with a bipolar twisted 
platinum/iridium electrode (FHC, Bowdoinham, ME). Baseline stimulation (100-μsec duration) was adjusted to 
30–40% (LTP) or 50% (LTD) of the maximum fEPSP amplitude. LTP was induced using different LTP protocols 
including: high frequency stimulation (100 Hz, 1 s) and theta burst stimulation (TBS) protocols. The TBS protocol 
consists of four trains at 5 Hz, each composed of four pulses at 100 Hz. Chemical mGluR-dependent LTD was 
evoked by application of (RS)-3,5-dihydroxyphenylglycine (DHPG, 100 μM) for 5 min. For LTD rescue exper-
iments, either MEK-inhibitor (U0126, Tocris Bioscience, 1 μM) or DMSO was added to the recording solution 
before starting the protocol. For NMDA-dependent LTD, the average LTP or LTD over the last 10 minutes of each 
measurement was used for analysis.
Data and statistical analysis. Spontaneous synaptic currents (IPSCs and EPSCs) data were analyzed with 
Mini Analysis (Synaptosoft Inc., Decatur, GA). All events were detected with a threshold >3× root-mean-square 
(RMS) of baseline noise. The detected currents were manually inspected to exclude false events. Passive and active 
membrane properties were analyzed offline using Clampfit 10 (Axon Instruments). Changes in synaptic strength 
were quantified for statistical comparisons by normalizing and averaging fEPSP slopes during the last 10 min of 
experiments relative to baseline.
All data are reported as mean ± SEM. Cumulative miniature and spontaneous synaptic current amplitude and 
inter-event interval (IEI) distributions were analyzed for statistical significance using the Kolmogorov-Smirnov 
(K-S) test (Statistica), and a conservative critical probability level of P < 0.01. All other statistical tests, including 
t-tests and one- or two-way (M)ANOVAs ([multivariate] analysis of variance), were performed using a critical 
probability of P < 0.05 and two-sided testing (SPSS version 20.0). Post-hoc Bonferroni correction analysis was 
performed only when an ANOVA yielded a significant (P < 0.05) main effect. Variance within each genotype 
or treatment was visualized in graphs. There were no overt differences in the variances between groups. All dis-
tributions were normal, either with 95% or 99% of confidence, and fulfilled the criteria for parametric testing. 
To detect or rule out meaningful, statistically significant differences between genotypes, we intended to include 
10–15 animals per genotype for behavioral experiments, 5–10 animals per genotype for biochemical experiments, 
and 10–20 cells per genotype for electrophysiological measures. In general, this allowed us to reliably detect effect 
sizes of >15%. Genotypes were unblinded only after analysis was completed. Randomization of animals was 
exclusively implemented by the only person who had access to the genotypes (M.E.), and was typically based on 
the date of birth and the random distribution of mutant and wild-type mice in each litter. P < 0.05 is indicated 
with one asterisk (*), P < 0.01 with two asterisks (**), and P < 0.001 with three asterisks (***). P values ≥ 0.05 
were considered as not rejecting the null hypothesis, and reported as not significant (N.S.).
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